QNTM
Quantum Biopharma Subordinate Voting SharesDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
The constructive view is still narrow: Lucid-MS appears to be moving toward a planned Phase 2 pathway after the IND submission, and the May 7 operating update showed better liquidity and lower burn. If the IND path stays on track and financing pressure remains contained, QNTM can retain speculative upside from a very low base.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +8.9.
What can break
Clinical and regulatory timing risk around Lucid-MS IND review and planned Phase 2 execution. [#PR-EARNINGS-2026-05-07]
Momentum
2
Value
41
Sentiment
80
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.35 · Bull $5.75 · Bear $2.60
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-11 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $12.50
Why
Momentum2 · Δ7d -0.3
Value41 · Δ7d +0.0
Sentiment80 · Δ7d +8.9
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
2
26% active weight
Current posture
7d trendFlat
Δ7d
-0.3
Δ21d
-79.6
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
80
34% active weight
Current posture
7d trendImproving
Δ7d
+8.9
Δ21d
-26.1
Why this grade
Composite grade D. Momentum 1.9 / Value 41.1 / Sentiment 80.4
Fundamentals (TTM)As of 2026-07-21
Fundamentals (TTM)
As of 2026-07-21
Market Cap
$19.25M
Beta
0.79
Shares Out
6.4M
P/E (TTM) · Derived
-0.4
P/S (TTM)
-
P/FCF (TTM) · Derived
-1.93
Rev YoY
-
EPS YoY
-12.8%
Gross Margin
-
Op Margin
-
Net Debt
-$4.3M
Current Ratio
0.63
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology